Suppr超能文献

基于 SEER 数据库的研究:甲状腺癌既往史对原发性肝癌患者生存的影响。

Effect of prior thyroid cancer on survival of primary liver cancer: a study based on the SEER database.

机构信息

Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, 182 Chunhui Road, Longmatan District, Luzhou, 646000, People's Republic of China.

出版信息

Sci Rep. 2022 Aug 16;12(1):13887. doi: 10.1038/s41598-022-17729-4.

Abstract

To explore the effect of prior thyroid cancer on the survival of primary liver cancer (PLC). Eligible PLC patients were selected from the Surveillance, Epidemiology, and End Results (SEER) database during 2004-2016. Propensity score matching (PSM) was used to create a highly comparable control group that PLC patients without prior thyroid cancer. All PLC patients were divided into three groups based on the survival information: (1) PLC-specific death; (2) death due to other causes; (3) alive. The effect sizes were presented by the corresponding hazard ratio (HR) and 95% confidence intervals (CI). Totally, 142 PLC patients with prior thyroid cancer and 1420 PLC patients without prior thyroid cancer were included. During the follow-up period, 714 (45.71%) PLC patients died of liver cancer while 638 (40.85%) PLC patients were alive. Median survival time for PLC patients was 11.00 months, respectively. PLC patients with prior thyroid cancer have a lower risk of death (HR = 0.64; 95% CI: 0.48-0.86). Subgroup analyses stratified by gender displayed the similar relation in female patients with PLC. Prior thyroid cancer may be a protective factor for liver cancer death in PLC patients, especially in female patients.

摘要

探讨甲状腺癌既往史对原发性肝癌(PLC)患者生存的影响。本研究从 2004 年至 2016 年的监测、流行病学和最终结果(SEER)数据库中筛选出符合条件的 PLC 患者。采用倾向评分匹配(PSM)方法创建了一个与 PLC 患者无甲状腺癌既往史的高度可比的对照组。所有 PLC 患者根据生存信息分为三组:(1)PLC 特异性死亡;(2)因其他原因死亡;(3)存活。采用相应的风险比(HR)和 95%置信区间(CI)表示效应量。共纳入 142 例有甲状腺癌既往史的 PLC 患者和 1420 例无甲状腺癌既往史的 PLC 患者。在随访期间,714 例(45.71%)PLC 患者死于肝癌,638 例(40.85%)PLC 患者存活。PLC 患者的中位生存时间分别为 11.00 个月。有甲状腺癌既往史的 PLC 患者死亡风险较低(HR=0.64;95%CI:0.48-0.86)。按性别分层的亚组分析显示,女性 PLC 患者也存在类似的关系。甲状腺癌既往史可能是 PLC 患者肝癌死亡的保护因素,尤其是女性患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ccb/9381514/af87386c83ba/41598_2022_17729_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验